A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03547999
• News release

Abstracts/Posters/Presentations:

• Kristen R. Spencer, DO, MPH; Daniella E. Portal, BS; Christopher R. Heery, MD; Lynne M. Bauman, MS; Howard Hochster, MD; Elizabeth Poplin, MD; Usha Malhotra, MD; Richard B. Alexander, MD; David A. August, MD; Timothy Kennedy, MD; Miral Grandhi, MD; Russell C. Langan, MD; Edmund C. Lattime, PhD; Dirk F. Moore, PhD; Michael P. Kane, RPh, BCOP; Liesel Dudek, RN, OCN, CCRP; Sarah Nabeel; Darren Carpizo, MD, PhD. HCRN GI16-288: A phase II trial of perioperative CV301 vaccination in combination with nivolumab and systemic chemotherapy for resectable hepatic-limited metastatic colorectal cancer. Presented as a Clinical Trials (In Progress) Poster at the Society for Immunotherapy of Cancer (SITC) 2018 Meeting, November 7-11, 2018. Journal for ImmunoTherapy of Cancer 2018 6 (Suppl 1):114. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.